showed that lenalidomide bypasses the requirement of CD28 for tumor-infiltrating CD8+ T-cell activation and antitumor activity of PD-1 blockade, which suggests that lenalidomide combination is beneficial to overcome PD-1 resistant tumors infiltrated with CD28- exhausted T cells (206). This evidence concerns the gene CD28 and neoplasm.